Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 185 from a previous price target of $195 . Mizuho advised their investors in a research report released on Aug 10, 2016.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Company shares were Reiterated by Mizuho on Jul 19, 2016 to “Buy”, Firm has raised the Price Target to $ 195 from a previous price target of $193 .Goldman Initiated Jazz Pharmaceuticals plc – Ordinary Shares on Jun 6, 2016 to “Buy”, Price Target of the shares are set at $196.
On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.18 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $2.81. The company had revenue of $381.20 million for the quarter, compared to analysts expectations of $376.45 million. The company’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.41 EPS.
Jazz Pharmaceuticals plc – Ordinary Shares closed down -1.61 points or -1.07% at $149.02 with 4,27,724 shares getting traded on Monday. Post opening the session at $151.05, the shares hit an intraday low of $148.78 and an intraday high of $151.18 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jul 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $142.43 per share price. According to the SEC, on Jul 13, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 580 shares at $143.63 per share price. On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price, according to the Form-4 filing with the securities and exchange commission.